ArticleInvestigative ophthalmology & visual science2011
Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages.
Article in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Lymphangiogenesis Guidance Mechanisms and Therapeutic Implications in Pathological States of the Cornea.Cells · 2023Review
- A Facile and Highly Efficient Approach to Obtain a Fluorescent Chromogenic Porous Organic Polymer for Lymphatic Targeting Imaging.Molecules (Basel, Switzerland) · 2022Article
- TGFBIp mediates lymphatic sprouting in corneal lymphangiogenesis.Journal of cellular and molecular medicine · 2019Article
- Article
- CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.Angiogenesis · 2017Article
- Effect of sorafenib in a murine high risk penetrating keratoplasty model.International journal of ophthalmology · 2017Article
- Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling.Angiogenesis · 2016Article
- Intravital Imaging Reveals Dynamics of Lymphangiogenesis and Valvulogenesis.Scientific reports · 2016Article
- VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis.Journal of oral microbiology · 2016Article
- Promoting inflammatory lymphangiogenesis by vascular endothelial growth factor-C (VEGF-C) aggravated intestinal inflammation in mice with experimental acute colitis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Article
- MicroRNA-184 Regulates Corneal Lymphangiogenesis.Investigative ophthalmology & visual science · 2015Article
- Role of angiopoietin-2 in corneal lymphangiogenesis.Investigative ophthalmology & visual science · 2014Article
- Expression of vascular endothelial growth factor C in human pterygium.Histochemistry and cell biology · 2013Article
- Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Conjunctival lymphatic response to corneal inflammation in mice.Journal of ophthalmology · 2012Article
- Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.Investigative ophthalmology & visual science · 2011Article
- Very late antigen-1 mediates corneal lymphangiogenesis.Investigative ophthalmology & visual science · 2011Article
- Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.PloS one · 2011Article
- Article
- Increased lymphangiogenesis and hemangiogenesis in infant cornea.Lymphatic research and biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLymphangiogenesis (LG) accompanies many corneal diseases after inflammatory, infectious, or chemical insults and is a primary mediator of transplant rejection. The purpose of this study was to investigate whether there is a time window for therapeutic intervention of corneal LG and whether a combined blockade of VEGFR-2 and VEGFR-3 effectively suppresses early-, middle-, or late-stage LG.
methodsCorneal inflammatory neovascularization was induced by a standard suture placement model in mice. Neutralizing antibodies against VEGFR-3 and/or VEGFR-2 were administrated systemically with the treatment started at postoperative day 0, day 7, or day 14. Whole mount corneas were sampled for immunofluorescence microscopic studies using LYVE-1 (a lymphatic marker) antibodies. Digital images were analyzed by software.
resultsBoth VEGFR-3 and VEGFR-2 were involved in corneal suture-induced inflammatory LG. Their combined blockade led to a significant inhibition of both early- and middle-stage LG while demonstrating no effect on late-stage LG.
conclusionsCorneal inflammatory LG has a discrete time window for intervention therapy. Although it is important to start the treatment as soon as possible, interventions initiated in the middle of the LG process are still effective. These novel findings will shed some light on our understanding of inflammatory LG and the development of new therapeutic protocols for LG-related diseases at different stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.